33621-61-3

Basic information

• Product Name: 2-AMINO-5-(4-CHLOROPHENYL)-1 3 4-OXADIA&
• Synonyms: 2-AMINO-5-(4-CHLOROPHENYL)-1 3 4-OXADIA&;5-(4-Chorophenyl)-1,3,4-oxadiazol-2-amine;5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-amine, 1-(5-Amino-1,3,4-oxadiazol-2-yl)-4-chlorobenzene
• CAS NO: 33621-61-3
• Molecular Formula: C₈H₆ClN₃O
• Molecular Weight: 195.60574
• Mol File: 33621-61-3.mol
• Article Data: 43

Chemical Properties

• Melting Point: 245°C (dec.)
• Boiling Point: 358.3 °C at 760 mmHg
• Flash Point: 170.5 °C
• Appearance: /
• Density: 1.415 g/cm³
• PKA: -1.42±0.26(Predicted)
• CAS DataBase Reference: 2-AMINO-5-(4-CHLOROPHENYL)-1 3 4-OXADIA&(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-5-(4-CHLOROPHENYL)-1 3 4-OXADIA&(33621-61-3)
• EPA Substance Registry System: 2-AMINO-5-(4-CHLOROPHENYL)-1 3 4-OXADIA&(33621-61-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 33621-61-3(Hazardous Substances Data)

Usage

General Description

2-AMINO-5-(4-CHLOROPHENYL)-1,3,4-OXADIA& is a chemical compound that is characterized by its three-ring structure and contains an amino group and a chlorine-substituted phenyl group. It is known for its potential biological activity and is commonly used in pharmaceutical research and drug development. 2-AMINO-5-(4-CHLOROPHENYL)-1 3 4-OXADIA& has been studied for its potential anti-cancer, anti-inflammatory, and antiviral properties. Additionally, it has shown promise in the treatment of various neurological disorders. Its unique structure and versatile properties make it a valuable target for further research and exploration in the field of medicinal chemistry.

Upstream product

• 64310-32-3 1-(4-chlorobenzoyl)thiosemicarbazide 
• 563-41-7 semicarbazide hydrochloride 
• 122-01-0 4-chloro-benzoyl chloride 
• 104-88-1 4-chlorobenzaldehyde 
• 506-68-3 bromocyane 
• 536-40-3 4-chlorobenzoic acid hydrazide 
• 1126-46-1 Methyl 4-chlorobenzoate 
• 74-11-3 para-chlorobenzoic acid 
• 4426-72-6 hydrazine carboxamide 
• 199339-17-8 2-[(Z)-5-(4-Chloro-phenyl)-[1,3,4]oxadiazol-2-ylimino]-5-methyl-thiazolidin-4-one 
• 23275-53-8 5-(4-chlorophenyl)-1,2,4-oxadiazol-3-amine 
• 5315-86-6 4-chlorobenzaldehyde semicarbazone 
• 855737-94-9 1-(4-chloro-benzoyl)-S-methyl-iso thiosemicarbazide 
• 141-52-6 sodium ethanolate 

Downstream Products

• 53297-67-9 6-(3-chloro-phenyl)-2-(4-chloro-phenyl)-[1,3,4]oxadiazolo[3,2-a][1,3,5]triazine-5,7-dione 
• 51324-06-2 2-<4-Chlor-phenyl>-5-oxo-7-aethoxycarbonyl-1,3,4-oxadiazolo<3,2-a>pyrimidin 
• 51323-97-8 2-(4-chloro-phenyl)-[1,3,4]oxadiazolo[3,2-a]pyrimidin-5-one 
• 72481-50-6 [5-(4-chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-phosphorimidic acid trichloride 
• 72481-55-1 [5-(4-chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-phosphoramidic acid dichloride 
• 75821-09-9 [5-(4-chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-nitroso-amine 
• 63776-61-4 4-acetylamino-N-[5-(4-chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-benzenesulfonamide 
• 53961-87-8 2,2,2-Trichloro-N-[5-(4-chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-acetamide 
• 89335-12-6 N¹-(5-p-chlorophenyl-1,3,4-oxadiazol-2-yl)thiourea 
• 199339-05-4 2-Bromo-N-[5-(4-chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-propionamide 
• 199338-99-3 2-Chloro-N-[5-(4-chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-2-phenyl-acetamide 
• 201343-16-0 5-(4'-chlorophenyl)-N-(1,3-dithiolan2-ylidene)-1,3,4-oxadiazol-2-amine 
• 752200-22-9 [5-(4-chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-dithiocarbamic acid 

Relevant articles and documents

In Silico Study and In Vitro Evaluation of Novel Synthesized Quinolone Derivatives Having Five-Membered Heterocyclic Moieties

Infectious diseases are caused by pathogens, such as viruses, bacteria, fungi, and parasites. Quinolones work by inhibition of bacterial topoisomerase IV and/or gyrase, a group of oxadiazole derivatives were incorporated into C7 piperazine ring of Gatiflo

Synthesis, in vitro α-glucosidase inhibitory potential and molecular docking studies of 2-amino-1,3,4-oxadiazole derivatives

Background: In the recent past, we have synthesized and reported different derivatives of oxadiazoles as potential α-glucosidase inhibitors, keeping in mind, the pharmacological aspects of oxadiazole moiety and in continuation of our ongoing research on the chemistry and bioactivity of new heterocyclic compounds. Methods: 1,3,4-Oxadiazole derivatives (1-14) have been synthesized and characterized by different spectroscopic techniques such as1 H-,13 C-NMR and HREI-MS. Results: The synthetic derivatives were screened for α-glucosidase inhibitory potential. All compounds exhibited good inhibitory activity with IC50 values ranging between 0.80 ± 0.1 to 45.1 ± 1.7 μM in comparison with the standard acarbose having IC50 value 38.45 ± 0.80 μM. Conclusion: Thirteen compounds 1-6 and 8-14 showed potential inhibitory activity as compared to the standard acarbose having IC50 value 38.45 ± 0.80 μM, however, only one compound 7 (IC50 = 45.1 ± 1.7 μM) was found to be less active. Compound 14 (IC50 = 0.80 ± 0.1 μM) showed promising inhibitory activity among all synthetic derivatives. Molecular docking studies were also conducted for the active compounds to understand the ligand-enzyme binding interactions.

Synthesis of indole-tethered [1,3,4]thiadiazolo and [1,3,4]oxadiazolo[3,2-a]pyrimidin-5-one hybrids as anti-pancreatic cancer agents

New indole-tethered [1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one (8a-j) and [1,3,4]oxadiazolo[3,2-a]pyrimidin-5-one hybrids (9a-e) were synthesized using [4+2] cycloaddition reactions of functionalized 1,3-diazabuta-1,3-dienes with indole-ketenes. All molecul